Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct 31;12(10):2448-2453.
doi: 10.21037/tcr-23-1279. Epub 2023 Oct 3.

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?

Roy Elias  1 , Emmanuel S Antonarakis  2
Affiliations
Editorial

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?

Roy Elias et al. Transl Cancer Res. .
No abstract available

Keywords: Metastatic castration-resistant prostate cancer (mCRPC); homologous repair deficiency (HRD); poly-ADP ribose polymerase inhibitors (PARPi); rucaparib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1279/coif). ESA has served as a paid consultant/advisor to Aikido Pharma, Constellation, Corcept Therapeutics, EcoR1, Exact Sciences, Foundation Medicine, Global Life Sciences, Hookipa Pharma, KeyQuest Health, Menarini Silicon Biosystems, Propella Therapeutics, z-Alpha, UroWebinar, MJH Events, PER, Research to Practice, Blue Earth Diagnostics, CM Propel and Ismar; has received research funding (to his institution) from Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Clovis, Constellation Pharma, MacroGenics, Merck, Orion, Sanofi, Aadi Biosciences, Amgen, Janssen, Pfizer and Tempus; and is a co-inventor of a biomarker technology that has been licensed to Qiagen. The other author has no conflicts of interest to declare.

Comment on

  • Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
    Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators. Fizazi K, et al. N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16. N Engl J Med. 2023. PMID: 36795891 Free PMC article. Clinical Trial.

References

    1. US Food and Drug Administration. FDA. FDA; 2020 [cited 2023 Jul 19]. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro...
    1. US Food and Drug Administration. FDA. FDA; 2020 [cited 2023 Jul 19]. FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grant...
    1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2020;382:2091-102. 10.1056/NEJMoa1911440 - DOI - PubMed
    1. Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 2020;38:3763-72. 10.1200/JCO.20.01035 - DOI - PMC - PubMed
    1. Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med 2023;388:719-32. 10.1056/NEJMoa2214676 - DOI - PMC - PubMed